首页> 外国专利> METHOD FOR THE IDENTIFICATION OF CD4+ REGULATORY T-CELLS FOR USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

METHOD FOR THE IDENTIFICATION OF CD4+ REGULATORY T-CELLS FOR USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

机译:鉴定用于治疗炎症和自身免疫性疾病的CD4 +调节性T细胞的方法

摘要

The present invention relates to a method for identifying CD4+ Treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue A to identify CD4+ Treg cells with migratory in character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue A and/or distinct tissue that is not vicinal though has migratory Treg communication with target tissue A, v) analysing samples from peripheral blood, tissue C, to identify CD4+ Treg cells with migratory character and/or functional character where the Treg cells are also emigrant from target tissue A, vi) analysing sample(s) from tissue compartments A and/or B and C, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to CD4+ Treg cells of target tissue A origin and/or tropism, to identify emigrant CD4+ Treg cell populations of target tissue A, to identify emigrant CD4+ Treg cell populations with propensity to immigrate to target tissue A, to identify a migratory and/or functional defect in the CD4+ Treg cell population identified as expressing migratory and/or functional elements specific for target tissue A in any of tissue A, B or C, and whereby a combination of surface or intracellular markers on CD4+ Treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in CD4+ Treg cell populations suitable for use as starting material in cellular immunotherapy.
机译:本发明涉及一种鉴定适合用作细胞免疫疗法起始材料的CD4 + Treg细胞的方法,该方法包括:i)分析来自靶组织A的样品,以鉴定患病组织之间具有迁移特性的CD4 + Treg细胞,收集淋巴管,外周血,与患病目标组织A相邻的不同组织和/或虽然与目标组织A具有迁移性Treg连通但不是邻近的独特组织,v)分析来自外周血,组织C的样品,以鉴定具有迁移特性的CD4 + Treg细胞和/或功能特征,其中Treg细胞也从目标组织A移出,vi)分析组织隔室A和/或B和C的样品,这些样品在分析或物理上消耗了胸腺的移出物和/或来自组织的移出物外周血至淋巴结,以限制对靶组织A起源和/或嗜性的CD4 + Treg细胞的分析,以鉴定移出的CD4 + Treg细胞p靶组织A的产物,以鉴定倾向于迁移到靶组织A的移民CD4 + Treg细胞群体,以鉴定被鉴定为表达针对靶组织的迁移和/或功能元件的CD4 + Treg细胞群体的迁移和/或功能缺陷在组织A,B或C中的任何一个中都为A,从而确定了CD4 + Treg细胞上表面或细胞内标志物的组合,该组合确定了CD4 + Treg细胞中应该存在哪些表面或细胞内标志物以及哪些表面不应该存在群体适合用作细胞免疫治疗的起始材料。

著录项

  • 公开/公告号EP3131560B1

    专利类型

  • 公开/公告日2018-11-14

    原文格式PDF

  • 申请/专利权人 GENOVIE AB;

    申请/专利号EP20150718837

  • 发明设计人 JARVIS REAGAN MICHEAL;THÖRN MAGNUS;

    申请日2015-04-16

  • 分类号A61K35/14;C12N5/0783;A61K45;G01N33/68;A61K39;

  • 国家 EP

  • 入库时间 2022-08-21 12:27:50

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号